Scaling up primary HPV DNA screening and self-sampling for cervical cancer in Peru: Coverage, cost-utility, and budget impact analysis using public data sources
Journal of Medical Screening · 29.10.2026
DOI: 10.1177/09691413261494992 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Screening, online erschienen am 29.10.2026. Verfasst von Víctor Juan Vera-Ponce und 5 weiteren Autor:innen. Beteiligte Einrichtung: Facultad de Medicina (FAMED), Universidad Nacional Toribio Rodríguez de Mendoza de Amazonas (UNTRM), Amazonas, Peru. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
Objectives
To estimate cervical screening coverage and inequities among Peruvian women aged 30–49 years and evaluate lifetime cost-utility and 5-year budget impact of scaling up HPV DNA testing, including self-sampling.
Setting
Peru, using national ENDES (Demographic and Family Health Survey) data and public sources.
Methods
We linked a cross-sectional ENDES 2015–2024 analysis to a public-payer decision model. Up-to-date screening was Pap or visual inspection with acetic acid within 3 years, or molecular HPV testing within 5 years. A screening decision tree and lifetime state-transition (Markov) model compared current practice with HPV self-sampling, clinician-collected testing, and hybrid expansion. We estimated costs, quality-adjusted life-years (QALYs), sequential incremental cost-effectiveness ratios (ICERs), probabilistic optimality, and budget impact at S/ 25,007 (Peruvian soles) / QALY.
Results
In 2024, 63.6% were up to date, 36.4% underscreened, 15.0% never screened, and 12.9% reported recent molecular HPV testing. The efficiency frontier was current practice, hybrid expansion to 90%, and clinician-collected HPV testing at 90%; sequential ICERs were S/ 5434 and S/ 10,982/QALY. In 5000 simulations, clinician-collected 90%, self-sampling 90%, and hybrid 90% had optimal-strategy probabilities of 69.46%, 15.46%, and 13.38%. Annualized budget impact was S/ 24.44 million for hybrid 90% and S/ 67.17 million for clinician-collected 90%.
Conclusions
Clinician-collected HPV testing at 90% maximized expected net monetary benefit under modeled assumptions, while hybrid expansion required less short-term expenditure. Policy should balance lifetime efficiency, feasibility, affordability, and linkage to diagnosis and treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Facultad de Medicina (FAMED), Universidad Nacional Toribio Rodríguez de Mendoza de Amazonas (UNTRM), Amazonas, Peru.
- Facultad de Odontología, Universidad Nacional Toribio Rodríguez de Mendoza de Amazonas (UNTRM), Amazonas, Peru.
ORCID-Profile: Víctor Juan Vera-Ponce
Zitieren
APA
Vera-Ponce, V. J., Ballena-Caicedo, J., García-Rodríguez, M., Sagastegui Jauregui, J. D., Padilla, W. O., & Zuzunaga-Montoya, F. E. (2026). Scaling up primary HPV DNA screening and self-sampling for cervical cancer in Peru: Coverage, cost-utility, and budget impact analysis using public data sources. Journal of Medical Screening. https://doi.org/10.1177/09691413261494992
Vancouver
Vera-Ponce VJ, Ballena-Caicedo J, García-Rodríguez M, Sagastegui Jauregui JD, Padilla WO, Zuzunaga-Montoya FE. Scaling up primary HPV DNA screening and self-sampling for cervical cancer in Peru: Coverage, cost-utility, and budget impact analysis using public data sources. Journal of Medical Screening. 2026. doi:10.1177/09691413261494992
BibTeX
@article{VeraPonce2026,
author = {Vera-Ponce, Víctor Juan and Ballena-Caicedo, Jhosmer and García-Rodríguez, Marcos and Sagastegui Jauregui, Julio David and Padilla, Witre Omar and Zuzunaga-Montoya, Fiorella E},
title = {Scaling up primary HPV DNA screening and self-sampling for cervical cancer in Peru: Coverage, cost-utility, and budget impact analysis using public data sources},
journal = {Journal of Medical Screening},
year = {2026},
doi = {10.1177/09691413261494992}
}
EUVIMED